Cue Biopharma is trading at $33.39, up 5.30%, rebounding after positive CUE-221 Phase 2 results announced September 20, which showed statistically significant efficacy and favorable safety findings.
- The stock remains highly volatile following recent sharp moves.
- The broader biotech sector is declining, while company-specific optimism is outweighing sector pressure.
- No new company announcement was identified for September 24, 2026.